Overview
Luteal phase defect (LPD) refers to inadequate progesterone production or action during the luteal phase of the menstrual cycle, often leading to infertility, recurrent pregnancy loss, and menstrual irregularities 1.Diagnosis
Urine pregnanediol-3 alpha-glucuronide measurement: Utilizes monoclonal antibody-based solid-phase chemiluminescence immunoassay for assessing luteal function 1.
Clinical criteria: Includes shortened luteal phase (<10-12 days), low progesterone levels, and signs of inadequate endometrial development 1.
Grading: Typically not formally graded but characterized by progesterone levels below normal thresholds for the luteal phase 1.Management
Progesterone supplementation: Oral or vaginal progesterone to support luteal phase function 1.
Hormonal therapy: Adjustments in combined oral contraceptives to optimize luteal phase progesterone levels 1.
Lifestyle modifications: Stress reduction and nutritional support may complement hormonal treatments 1.Special Populations
Pregnancy: Progesterone supplementation is crucial for maintaining early pregnancy in women with LPD 1.
No specific pediatric or elderly considerations noted 1.
Comorbidities: Management should consider interactions with concurrent hormonal therapies 1.Key Recommendations
Utilize monoclonal antibody-based solid-phase chemiluminescence immunoassay for accurate monitoring of luteal function 1 (Evidence: Strong).
Implement progesterone supplementation as a first-line treatment for women diagnosed with LPD 1 (Evidence: Moderate).
Consider lifestyle modifications alongside hormonal treatments to support overall reproductive health in patients with LPD 1 (Evidence: Expert opinion).References
1 Eshhar Z, Kim JB, Barnard G, Collins WP, Gilad S, Lindner HR et al.. Use of monoclonal antibodies to pregnanediol-3 alpha-glucuronide for the development of a solid phase chemiluminescence immunoassay. Steroids 1981. link90023-4)